Supernus Pharmaceuticals (SUPN) investor relations material

Portfolio overview and growth trajectory

• Focused on CNS with four key growth products: Qelbree (ADHD), ZURZUVAE (postpartum depression), Onapgo (advanced Parkinson's), and GOCOVRI (OFF episodes/dyskinesia).

• Achieved record year in 2025 and expects continued growth into 2026 and beyond.

• Qelbree is in early market penetration with significant growth potential; ZURZUVAE is the only oral product for postpartum depression.

• Onapgo launched in April 2025, rebounding after a supply disruption, with momentum building in Q2.

• Combined peak sales potential for the portfolio estimated at $1.5 billion or more.

Financial position and business development

• Revenue guidance for 2025 is $840–$870 million, with strong cash position and no debt.

• Business development is a top priority, focusing on commercial and late-stage assets.

• Capacity for deals in the $500–$600 million range for single assets, potentially higher for multi-asset/company deals using leverage.

• Theoretical deal size could reach billions if supported by strong cash flows.

Onapgo performance and market dynamics

• Onapgo targets a new segment in Parkinson's with a subcutaneous apomorphine infusion device.

• Differentiated from competitors by drug mechanism and patient profile; can be used adjunctively with oral therapies.

• Rebounding from supply issues, with prescription momentum and healthy demand pipeline.

• Conversion rate from start forms to shipments is 45–50%, slightly above industry average.

• Compliance and discontinuation rates expected to align with European experience (25–33% discontinuation).

• Second supplier sNDA submission planned for Q3 2026, with approval expected by mid-2027, increasing capacity.